Atopic dermatitis: skin care and topical therapies.

Q1 Medicine
David M Fleischer, Jeremy Udkoff, Jenna Borok, Adam Friedman, Noreen Nicol, Jeffrey Bienstock, Peter Lio, Megha M Tollefson, Lawrence F Eichenfield
{"title":"Atopic dermatitis: skin care and topical therapies.","authors":"David M Fleischer,&nbsp;Jeremy Udkoff,&nbsp;Jenna Borok,&nbsp;Adam Friedman,&nbsp;Noreen Nicol,&nbsp;Jeffrey Bienstock,&nbsp;Peter Lio,&nbsp;Megha M Tollefson,&nbsp;Lawrence F Eichenfield","doi":"10.12788/j.sder.2017.035","DOIUrl":null,"url":null,"abstract":"<p><p>Atopic dermatitis (AD) pathogenesis is strongly influenced by Type 2 innate lymphoid cell and T-helper cell type 2 lymphocyte-driven inflammation and skin barrier dysfunction. AD therapies attempt to correct this pathology, and guidelines suggest suggest basics of AD therapy, which include repair of the skin barrier through bathing practices and moisturizers, infection control, and further lifestyle modifications to avoid and reduce AD triggers.While some patients' AD may be controlled using these measures, inflammatory eczema including acute flares and maintenance therapy in more severe patients are treated with topical pharmacologic agents such as topical corticosteroids, topical calcineurin inhibitors, and, more recently, topical PDE-4 inhibitors. This model of basic skin therapy and, as needed, topical pharmacologic agents may be used to treat the vast majority of patients with AD and remains the staple of AD therapy.</p>","PeriodicalId":21714,"journal":{"name":"Seminars in cutaneous medicine and surgery","volume":"36 3","pages":"104-110"},"PeriodicalIF":0.0000,"publicationDate":"2017-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in cutaneous medicine and surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12788/j.sder.2017.035","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 7

Abstract

Atopic dermatitis (AD) pathogenesis is strongly influenced by Type 2 innate lymphoid cell and T-helper cell type 2 lymphocyte-driven inflammation and skin barrier dysfunction. AD therapies attempt to correct this pathology, and guidelines suggest suggest basics of AD therapy, which include repair of the skin barrier through bathing practices and moisturizers, infection control, and further lifestyle modifications to avoid and reduce AD triggers.While some patients' AD may be controlled using these measures, inflammatory eczema including acute flares and maintenance therapy in more severe patients are treated with topical pharmacologic agents such as topical corticosteroids, topical calcineurin inhibitors, and, more recently, topical PDE-4 inhibitors. This model of basic skin therapy and, as needed, topical pharmacologic agents may be used to treat the vast majority of patients with AD and remains the staple of AD therapy.

特应性皮炎:皮肤护理和局部治疗。
特应性皮炎(AD)的发病机制受2型先天淋巴细胞和t辅助细胞驱动的炎症和皮肤屏障功能障碍的强烈影响。阿尔茨海默病治疗试图纠正这种病理,指南建议了阿尔茨海默病治疗的基本方法,包括通过沐浴和保湿剂修复皮肤屏障,控制感染,以及进一步改变生活方式以避免和减少阿尔茨海默病的诱因。虽然一些患者的AD可以通过这些措施得到控制,但在更严重的患者中,包括急性发作和维持治疗在内的炎性湿疹需要使用局部药物治疗,如局部皮质类固醇、局部钙调磷酸酶抑制剂,以及最近的局部PDE-4抑制剂。这种基本的皮肤治疗模式,如有需要,局部药物可用于治疗绝大多数阿尔茨海默病患者,并且仍然是阿尔茨海默病治疗的主要方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.90
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊介绍: Seminars in Cutaneous Medicine and Surgery (SCMS) presents well-rounded and authoritative discussions of important clinical areas, especially those undergoing rapid change in the specialty. Each issue, under the direction of the Editors and Guest Editors selected because of their expertise in the subject area, includes the most current information on the diagnosis and management of specific disorders of the skin, as well as the application of the latest scientific findings to patient care.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信